Can Psychedelics Interfere With Cancer? The Nervous System Connection
A new scientific review explores whether psychedelic substances could disrupt nervous system signals utilized by cancer tumors to spread, while highlighting proven mental health benefits for terminal patients.
A novel scientific review puts forward a compelling hypothesis suggesting that cancerous tumors may "learn" to tap into the nervous system and utilize it to spread throughout the body. This finding raises a groundbreaking question in cancer research: could psychedelic substances, known for their profound impact on the brain and nervous system, disrupt this process and combat the tumors themselves? Researchers emphasize that this is merely a hypothesis, and the investigation remains in its earliest stages.
The most solid foundation for using psychedelics in the context of cancer does not involve the tumor itself, but rather psychological distress. Controlled clinical studies have already demonstrated that supervised therapy using psilocybin, the active compound in magic mushrooms, can produce rapid and sustained reductions in anxiety, depression, and existential distress among terminal patients. Participants reported a renewed sense of meaning, acceptance, and connection following treatments that combine the psychedelic compound with structured psychological support.
The novel concept presented in the review relies on a phenomenon known as "malignant synaptic plasticity." In laboratory experiments, researchers observed that glioma brain tumor cells manage to integrate into neural networks and form synapse-like connections with neighboring neurons. A similar phenomenon has been documented in other types of cancer, such as prostate, breast, and pancreatic cancers, which are frequently innervated. The hypothesis suggests that if cancer exploits the nervous system, it might be possible to disrupt this communication.
Study authors firmly emphasize that current evidence does not support the routine integration of psychedelics into cancer treatment. Some pre-clinical studies have even yielded contradictory results, such as accelerated tumor growth under certain conditions. Furthermore, tangible safety risks exist, including temporary spikes in blood pressure and heart rate, as well as an increased risk of seizures among patients with brain tumors. The current objective is not a "mystical cure" but the improvement of quality of life, while the question of whether alleviating fear can impact the tumor itself requires extensive further research.
